VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

COSTEM 2022 | Challenges in developing CAR-T therapy for AML

Marion Subklewe, MD, Ludwig-Maximilians-University of Munich, Munich, Germany, describes current barriers to effective CAR-T therapy in acute myeloid leukemia (AML). There is currently no suitable target antigen that is not highly expressed in healthy cells and T cell function tends to decline as the disease progresses, reducing the efficacy of CAR-Ts. This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter